Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
With
Aspreva Pharmaceuticals
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
subjects who have completed 36 weeks of treatment in study WX17798, and who have demonstrated good symptom control with a stable prednisone dose for the final 4 weeks of that study.
You may not be if
regularly scheduled plasma exchange or intravenous immunoglobulin treatment;
medical condition, adverse event or intolerance of double-blind treatment which would preclude continuation.
